drugset / Trial / NCT00078039
Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 3 mg | Oral |
| Subject | Paliperidone | Unknown | 6 mg | Oral |
| Subject | Paliperidone | Unknown | 9 mg | Oral |
| Subject | Paliperidone | Unknown | 12 mg | Oral |